Futibatinib in Patients Previously Enrolled in an Antecedent Futibatinib as Monotherapy or Combination Therapy.
Running, not enrolling · Phase 2/Phase 3
Conditions studied: Advanced/Metastatic Cancer
In brief
This is a nonrandomized, open-label, multicenter rollover study for patients who received futibatinib as monotherapy or as combination therapy in a Taiho-sponsored futibatinib study.
Key facts
- Study ID
- NCT06506955
- Run by
- Taiho Oncology, Inc.
- People needed
- 15
- Starts
- 2024-10-01
- Expected to finish
- 2027-04-30
- Last updated by the study team
- 2026-07-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Provide written informed consent.
- Receiving futibatinib as monotherapy or as combination therapy in an antecedent futibatinib study and deriving clinical benefit with no undue risk as assessed by the investigator.
- Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to receiving treatment. Both males and females of reproductive potential must agree to use effective birth control during study treatment and for a specified time after the last dose of study treatment.
- Ability to take medications orally (PO) (feeding tube is not permitted).
You may not qualify if…
- Has met any discontinuation criteria within the antecedent futibatinib study.
Where it is running
- University of California, San Francisco (UCSF) — San Francisco, California, United States
- Institut Paoli-Calmettes — Marseille, France
- Institut De Cancerologie Strasbourg — Strasbourg, France
- Severance Hospital — Seoul, South Korea
- Hospital Universitari, Vall d'Hebron — Barcelona, Spain
- Centro Integral Oncologico — Madrid, Spain
- Royal Marsden NHS Foundation Trust — London, United Kingdom
- Sarah Cannon Research Institute UK — London, United Kingdom
- University College London Hospitals NHS Foundation Trust — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.